Formulation Optimization and in Vivo Evaluation of Controlled Release Tablet of Linagliptin: A Review

ABSTRACTLinagliptin is a selective and potent inhibitor of dipeptidyl peptidase-4 (DPP-4) that isapproved for the management of type 2 diabetes mellitus (T2DM). Like other agents withinthis therapeutic class, linagliptin enhances endogenous incretin function by preventing theenzymatic breakdown of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide(GIP). This action leads to augmentation of glucose-dependent insulin secretion andsuppression of inappropriate glucagon release during hyperglycemic states. Linagliptin hasbeen shown to significantly reduce postprandial glucose concentrations, fasting plasmaglucose, and glycated haemoglobin (HbA1c) levels when used either alone or in combinationwith other oral antidiabetic agents or insulin. A notable pharmacokinetic attribute oflinagliptin is its predominantly non-renal elimination through the enterohepatic pathway,which removes the requirement for dose modification in patients with renal impairment andoffers an important clinical advantage compared with other DPP-4 inhibitors. Furthermore,linagliptin exhibits strong and sustained binding to the DPP-4 enzyme, allowing prolongedinhibition with once-daily administration. Increasing evidence also suggests additionalpleiotropic effects, including anti-inflammatory and antifibrotic actions, as well as potentialcardiovascular and renal protective benefits beyond glycemic regulation. This reviewsummarizes the pharmacological characteristics, mechanism of action, clinical efficacy,safety profile, and emerging therapeutic perspectives of linagliptin in the treatment of type 2diabetes mellitus.